Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

NCT07311993 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Iopofosine I 131
DRUG: CLR 125

Sponsor

Cellectar Biosciences, Inc.